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Purpose: To describe the  reliability of blood bicarbonate pharmacokinetics in response to 
sodium bicarbonate (SB) supplementation across multiple occasions and assess, using 
putative thresholds, whether individual variation indicated a need for individualised ingestion 
timings. Methods: Thirteen m en (age 27±5 y; body mass (BM) 77.4±10.5 kg; height 1.75
±0.06 m) ingested 0.3 g·kg       -1BM SB in gelatine capsules on 3 occasions. One hour after a 
standardised meal, venous blood was obtained before and every 10 min following ingestion 
for 3 h, then every 20 min for a further hour. Time-to-peak (Tmax), absolute-peak (Cmax), 
absolute-peak-change (∆Cmax) and area under the curve (AUC) were analysed using mixed 
models, intraclass correlation coefficient (ICC), coefficient of variation (CV) and typical 
error. Individual variation in pharmacokinetic responses was assessed using Bayesian 
simulation with multilevel models with random intercepts. Results: No significant 
differences between sessions were shown for blood bicarbonate regarding Cmax, ∆Cmax or 
AUC (p>0.05), although Tmax occurred earlier in SB2 (127±36 min) than in SB1 (169±54 
min, p=0.0088) and SB3 (159±42 min, p=0.05). ICC, CV and typical error showed moderate 
to poor reliability. Bayesian modelling estimated that >80% of individuals from the 
population experience elevated blood bicarbonate levels above + 5 mmol∙L-1 between 75-240 
min after ingestion, and between 90-225 min above +6 mmol∙L-1. Conclusion: Assessing SB 
supplementation using discrete values showed only moderate reliability at the group level, 
and poor reliability at the individual level, while Tmax was not reproducible. However, when 
analysed as modelled curves, a 0.3 g·kg-1BM dose was shown to create a long-lasting window 
of ergogenic potential, challenging the notion that SB ingestion individualised to time-to-
peak is a necessary strategy, at least when SB is ingested in capsules. 
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Sodium bicarbonate (SB) is an effective nutritional supplement to improve exercise 
performance and capacity during high intensity exercise (1-3). Acute ingestion of SB incurs an 
increase in blood pH and bicarbonate within approximately 30-60 mins which lasts up to 
several hours (4, 5).The metabolic alkalosis induced by SB ingestion leads to an increased 
efflux of lactate and hydrogen ions (H+) out of the working muscles during exercise (6), which 
can delay the negative impact of muscle acidosis on contractile processes (7) and improve 
exercise performance.  
Despite the known ergogenic potential of SB supplementation, recent studies are 
moving away from typical mean group analyses towards individualised approaches (8, 9). This 
is due to the identification of factors that may moderate the ergogenic effect of SB, including 
variability in blood responses following SB ingestion. The time course of blood bicarbonate 
responses to acute SB ingestion indicates large variability between individuals, with peak 
bicarbonate concentration occurring between 75 and 180 minutes when ingested in capsules 
(4) and between 10 and 140 minutes (5, 10) in solution using the commonly employed relative
dose of 0.3 g·kg-1 body mass (BM) of SB. Coupled with recent evidence demonstrating 
consistent intraindividual response to the same dose taken on different days, it has been 
suggested that the optimal time to perform exercise would be at this time at which blood 
bicarbonate peaks (8). However, only one study to date has investigated the reproducibility of 
these blood response across two sessions providing SB in solution (5). In addition, the time-
course responses to SB ingestion when meal ingestion is controlled remain unknown, a 
procedure that is likely used by most athletes in real competitive situations. Thus, more 
information about the consistency of the time-course responses to SB ingestion is warranted, 

























The ergogenic effects of SB have been suggested to be dependent on a minimum 
increase of circulating bicarbonate, with an increase of +5 mmol·L-1 being considered a zone of 
potential ergogenic benefit, and increases above 6 mmol·L-1 being almost certainly ergogenic (4, 
11, 12). It is currently unclear whether the absolute increases at time to peak differ 
substantially from those generally seen at standardised time points. The mean +6.5 ± 1.3 
mmol·L-1 increase shown at time to peak by Gough, et al. (13) is similar to the increases shown 
following 60 min (+6.1 Dias, et al. (14); +5.1 Jones, et al. (4); +5.7 Gough, et al. (8)), 90 min 
(+6.5 Jones, et al. (4) +6.1 Gough, et al. (8) and 120 min (+6.5 Jones, et al. (4); +5.6 Gough, et 
al. (8)) with the same 0.3 g·kg-1BM dose. Furthermore, blood bicarbonate concentration was 
not shown to be different 60-, 120- and 180-min following SB supplementation in gelatine 
capsules (15), which raises questions as to whether ingestion timing is an important factor for 
the ergogenic effects of SB in this form. It remains to be determined whether blood bicarbonate 
is consistently increased close to peak, or above +6 mmol·L-1, for prolonged periods.   
Although time to peak in blood bicarbonate has been touted as a strategy to optimise 
SB ingestion (13), there are several limitations that may preclude its applicability to actual 
training or competition settings. Firstly, it requires athletes or coaches to have access to a 
reliable blood gas analyser and to perform a subsequent time-course measurement of blood 
bicarbonate responses to SB ingestion over several hours. This procedure is laborious, costly 
and not easily accessible for most athletes. Secondly, time to peak assumes that the increases in 
circulating SB are substantially greater when blood bicarbonate peaks than at standard time 
points, instead of assuming that blood bicarbonate will fluctuate around the peak value for a 
period of time. An in-depth analysis of the blood bicarbonate responses to SB ingestion could 
reveal whether the “window of ergogenicity” is limited to a fixed time point or extends across a 
broad time period following SB ingestion. This could provide important practical information 








To address these controversies, the aims of this investigation were to describe and 
determine the reliability of orally ingested SB pharmacokinetics over 4 hours using multiple 
testing occasions (including a placebo trial).  A secondary aim of this study was to assess 
whether individual variation in orally ingested SB pharmacokinetics indicated a need 
for individualised ingestion timings. Our hypothesis was that SB ingestion would result 
in a sustained increase in blood bicarbonate above the purported ergogenic thresholds. We 
also hypothesised that this pattern would result in inconsistent responses in Tmax, 




Twenty-four young, physically active, healthy men were screened for eligibility; three 111 
of them did not meet inclusion criteria, and six other candidates did not wish to partake in the 112 
study. Fifteen participants enrolled in the study, but one withdrew after the first session due to 113 
personal reasons while a second participant withdrew after the third session due to gastric 114 
distress associated with SB ingestion. Therefore, complete data were obtained for 13 115 
participants and used in all analyses herein reported (age = 27 ± 5 years; BM = 77.4 ± 10.5 kg; 116 
height = 1.75 ± 0.06 m; body mass index = 25.2 ± 2.9 kg·m2). Inclusion criteria were defined 117 
a priori as: healthy men aged 18 to 35 years. Exclusion criteria were defined a priori as: 118 
smoking, use of medications that may alter stomach pH and any diagnosed condition that could 119 
affect the gastrointestinal and blood pH balance. All volunteers were informed about the 120 
discomforts and risks associated with participation and thereafter provided written consent. 121 


























This was a crossover, placebo-controlled study in which volunteers visited the 
laboratory on four separate occasions, 2-7 days apart, to receive SB (on 3 occasions) or placebo 
(PL, on 1 occasion). To control for order effects, treatments were randomly assigned to each 
visit in a balanced fashion using the Latin square. Participants were requested to refrain from 
strenuous physical activity and alcohol intake in the 24h preceding each visit. They were also 
instructed to maintain a similar pattern of food intake on all days prior to the tests. Compliance 
with these requests was verbally confirmed with all participants. The participants arrived at the 
laboratory in the morning after an overnight fast, and a standardised breakfast (energy: 563 
kcal; protein: 9.3 g; carbohydrate: 89.6 g; fats: 8.9 g) was served to avoid variations in blood 
responses due to differences in food intake prior to the tests. One hour following the breakfast, 
blood samples were taken before and during 4 hours after the ingestion of SB or PL.  
Supplementation protocol 
Sodium bicarbonate (0.3 g∙kg-1 BM; Farmácia Analítica, Rio de Janeiro, Brazil) was 
given on three different visits while an identical number of capsules was provided in PL (each 
capsule containing 56 mg of corn flour; Farmácia Analítica, Rio de Janeiro, Brazil). 
Supplements were given in gelatine capsules identical in size and appearance. Participants had 
5 minutes to ingest all capsules. After ingestion of the last capsule, a stopwatch was started to 
control the exact times at which blood samples were to be taken. 
Blood sampling  
The cephalic vein was cannulated (catheter 20 G Safelet Nipro) and kept warm with the 
use of a forearm thermal blanket maintained at 48°C throughout the entire 4 h sampling period. 
A venous blood sample was taken for the determination of baseline blood parameters (i.e., 
before ingestion). The participants then ingested SB or PL in gelatine capsules along with 400 

























taken every 10 minutes for 3 hours, and then every 20 minutes in the 4th hour. Blood samples 
(1 ml) were collected in heparinised syringes and immediately analysed for pH and pCO2 using a 
blood gas analyser (RAPIDLab 348, Siemens, Germany). Quality controls were performed 
each experimental day prior to data collection. Blood bicarbonate was calculated using the 
Henderson-Hasselbalch equation. The inter-assay coefficient of variation of blood bicarbonate 
was 6.4% (determined over the 4-h period during the PL trial). Blood bicarbonate was defined a 
priori as the primary outcome. 
Side-effects 
Side-effects were recorded at the same time-points as blood collection using an adapted 
questionnaire (16). Participants rated the intensity of the following 13 symptoms from 0 (no 
effect) to 10 (very intense effect): nausea, dizziness, headache, flatulence, urge to defecate, 
belching, heartburn, bloating, stomach cramps, intestinal cramps, urge to vomit, vomiting, and 
diarrhoea. 
Statistical Analysis 
Data are presented as mean ± standard deviation. Area under the curve (AUC) was 
calculated for bicarbonate and pH using the trapezoid method. Mixed models (proc mixed, 
SAS University Edition) were used to compare the following variables between visits: baseline, 
time to peak (Tmax, defined as the first time in minutes that bicarbonate and pH variables took 
to reach its highest value), absolute peak (Cmax, defined as the highest value in bicarbonate 
and pH variables), absolute peak change (∆Cmax, defined as the absolute difference between 
baseline and Cmax) and AUC. Individuals were considered random factors and session (3 
levels; SB1, SB2, SB3) and time (blood collection time points) were fixed factors. Mixed 
models were also used to compare blood bicarbonate concentration at Tmax and 60, 90 and 120 
minutes after ingestion. To account for the time series nature of the data and subsequent 

























Autoregressive, Toeplitz and Unstructured) were tested to verify the model that best fit to each 
data set, according to the Bayesian Information Criterion (lowest BIC value). Pairwise 
comparisons adjusted by Tukey-Kraemer were used when a significant F-value was observed. 
Intraclass correlation coefficient (ICC), typical error using data from the 3 SB trials to determine 
within-subject reliability. Test-retest coefficient of variations (CV) were calculated using the 
mean square root method (17). The frequency of side-effects reported between visits, 
irrespective of intensity and duration, was analysed using the chi-square test. Side-effect scores 
for the 13 symptoms were summed within each visit and compared between visits using the 
Friedman Test. Statistical significance was accepted at p ≤ 0.05. Inter-trial reliability was 
assessed by calculating typical errors (sigma) and ICCs from level 0 and level 1 residuals in the 
mixed models. Since all blood pH data and analysis were similar that of blood bicarbonate, 
herein we report blood bicarbonate data only although blood pH data is included as 
supplemental material (Supplemental Digital Content 1 – Figure – Blood pH responses). 
To describe individual variation in the pharmacokinetic responses to orally ingested SB 
and assess the need for individualised ingestion timings, a Bayesian perspective was adopted. A 
Bayesian perspective best facilitated probabilistic questions such as the probability of an 
individual’s blood bicarbonate level exceeding a given absolute increase (i.e. +5 or +6 mmol·L-
1) or percentage increase within specific time windows. Using data collected across the 
participants’ three active testing sessions, Bayesian multilevel models with random intercepts 
and slopes were fitted using the brms package (18) in the programming language R. In contrast 
to treating observed data as independent points, it was assumed that changes in blood 
bicarbonate after SB ingestion followed a smooth response that could be adequately described 
by a polynomial function. Linear, quadratic, cubic and quartic models were fitted, with 
Watanabe-Akaike Information Criterion (WAIC) used to identify a cubic model as the best fit 

























model parameters. To reflect a lack of prior information, default improper flat priors were 
selected for population-level regression parameters and the LKJ-prior selected for the 
multivariate normal distribution covariance matrix between group-level parameters. Posterior 
estimates of size n=10,000 were generated for each parameter using MCMC sampling with 4 
chains and 3,500 iterations (warmup = 1,000 iterations). These posterior estimates described 
the typical (e.g. median) blood bicarbonate response representative of the group. To explore 
the likely range and distribution of responses across individuals from a similar population, 
posterior estimates were used to probabilistically sample regression parameters from a 
multivariate normal distribution. For each parameter set (n=10,000), 100 individual blood 
bicarbonate traces (each a cubic polynomial) were produced and the total pool of 1 million 
traces used to estimate probabilities that an individual’s blood bicarbonate increased above 
+5 and +6 mmol∙L-1. A threshold of 80% probability was selected to assist with interpretation 
of results and identify time windows where for practical purposes it could be concluded that 
the vast majority of individuals met the criteria. 
RESULTS 
Reliability  
Blood bicarbonate at baseline was not different between sessions (SB1 = 25.7 ± 2.4; 
SB2 = 25.0 ± 2.0; SB3 = 26.0 ± 1.7; PL = 25.4 ± 2.1 mmol·L-1; F = 0.74; p = 0.5348; Figure 
1). Reliability statistics were calculated for baseline (TE: 1.7 units, ICC: 0.26), Cmax (TE: 2.0 
units, ICC: 0.20), DeltaCmax (TE: 2.5 units, ICC: 0.1) and Tmax (TE: 38.7 units, ICC: 0.34). 
ICCs, typical error and CVs calculated for blood bicarbonate between sessions are presented 
in Table 1. 
Area under the curve was not different between SB sessions (SB1 = 1447 ± 364 
mmol·min·L-1; SB2 = 1468 ± 421 mmol·min·L-1; SB3 = 1210 ± 520 mmol·min·L-1; F = 0.87; 222 
p = 0.43; figure 1, panel B). No significant differences between sessions were shown for blood 223 
bicarbonate regarding Cmax (SB1 = 36.8 ± 2.8 mmol·L-1; SB2 = 35.5 ± 1.4 mmol·L-1; SB3 = 224 
35.2 ± 2.0 mmol·L-1; F = 2.65; p = 0.10; figure 1, panel C) or ∆Cmax (SB1 = 11.1 ± 2.7 mmol·L-225 
1; SB2 = 10.5 ± 2.5 mmol·L-1; SB3 = 9.3 ± 2.2 mmol·L-1; F = 1.30; p = 0.29, figure 1, panel 226 
D), although Tmax occurred significantly earlier in SB2 (127 ± 36 min) than in SB1 (169 ± 54 227 
min, p = 0.0088) and SB3 (159 ± 42 min, p = 0.05; Figure 2) (main effect of session: F = 5.83; 228 
p = 0.0086) (figure 1, panel E). 229 
Individual analysis showed substantial intra-individual variation for Tmax in blood 230 
bicarbonate following SB ingestion, despite the lack of statistical differences between sessions 231 
for mean values (figure 2). Moreover, a prolonged time period above the +5 mmol·L-1 (light 232 
grey blocks) and +6 mmol·L-1 (dark grey blocks) thresholds was shown in nearly all 233 
participants in all three sessions (figure 2). 234 
Tmax vs. standard time points 235 
Comparison between Tmax and standard time points showed statistically significant 236 
differences in absolute bicarbonate values between all prespecified time points (Tmax: 35.9 ± 237 
2.2 mmol·L-1; 60 min: 30.8 ± 2.4 mmol·L-1; 90 min: 32.1 ± 2.6 mmol·L-1; 120 min 33.0 ± 3.0 238 
mmol·L-1; F = 45.87; p < 0.0001), except for 90 vs 120 min (p = 0.1852). Delta change for 239 
blood bicarbonate was different between Tmax vs. all pre specified time points (all p < 0.001), 240 
but no significant differences were shown between 90 and 120 min (p = 0,1852; Figure 3). 241 
Modelling approaches  242 
Bayesian modelling and subsequent simulations estimate that over 80% of individuals 243 
from the population experience elevated blood bicarbonate levels greater than 5 mmol∙L-1244 
between 75 and 240 min after ingestion. For absolute increases greater than 6 mmol∙L-1, the 245 

























modelling and subsequent simulations with a multilevel cubic model are illustrated in Figure 
4. 
Side-effects 
All participants reported one or more side-effects in each of the three SB trials, with a 
total of 39 symptoms being reported in SB1, 46 symptoms in SB2 and 37 symptoms in SB3. 
No significant differences between sessions were shown for the frequency of side-effects 
symptoms (x² = 1.45, p < 0.485). The Friedman test showed that intensity of symptoms 
throughout the time-course was not different between visits (p = 0.7627; Supplemental Digital 
Content 2 - Figure – Side-effects).  
DISCUSSION 
This study is the first to investigate a 4-h time-course response of blood bicarbonate, 
pH and side-effects following the ingestion of 0.3 g·kg-1BM sodium bicarbonate in gelatine 
capsules on 3 distinct sessions. We hypothesised that, due to the dynamic nature of blood acid-
base regulation and natural fluctuation in blood bicarbonate concentration, a single time point 
for peak blood bicarbonate would not properly represent the sustained increase in blood 
bicarbonate following acute SB ingestion Jones, et al. (4). We also sought to gather further 
information on the within-subject consistency of blood bicarbonate responses to acute SB 
ingestion in gelatine capsules. Repeated administration of SB in gelatine capsules did not elicit 
consistent responses for bicarbonate Tmax, which is in agreement with our initial hypothesis, 
and potentially challenges the necessity of individualised ingestion timings. Overall, our results 
indicate that blood bicarbonate continuously rises for ~120-160 min after SB ingestion before 
reaching a plateau, with elevated values being shown until the end of the 4-h period.  
The Bayesian analysis revealed an interesting pattern of elevated probabilities of 

























after ingestion to the end of the measurement period. Although performance assessment was 
beyond the objectives of this study, our data might challenge the notion that a single time point 
at which blood bicarbonate peaks is necessary to optimise the ergogenic effects of SB. Instead, 
the Bayesian model and reliability analyses, collectively, suggest that it is not possible to 
accurately determine when peak blood bicarbonate has been reached since slight variations in 
blood bicarbonate, including the peak values, are most likely due to random error (owing to 
measurement error and biological variation) around the already elevated blood bicarbonate 
concentrations. Therefore, it appears that the ergogenic potential of SB is likely to be in place 
for at least 3 hours, starting ~60 min after ingestion. This finding is consistent with a previous 
study that measured blood bicarbonate for 3 hours in response to SB ingestion and found a 
similar plateau-shaped curve of increased blood bicarbonate (4). However, our data contrasts 
with another similar study that showed a trend towards a rapid decline in blood bicarbonate 
after reaching its peak (8). Perhaps the best explanation for the difference between these studies 
may be related to the form of SB administration. While our study and Jones, et al. (4) provided 
SB in gelatine capsules and found a more sustained increase in blood bicarbonate, Gough, et al. 
(8) provided SB in solution and found a more rapid profile of blood bicarbonate appearance and 
disappearance. These differences in the shape of the blood bicarbonate curves (i.e., more 
sustained vs. rapid decline) seems to also explain why the reliability of Tmax was poor in our 
study (random error around a long-lasting elevation in blood bicarbonate) in contrast with a 
good reliability in the study by Gough et al. (sharp peak and rapid decline allow a clear 
identification of Tmax). There is a slight difference in pharmacokinetics when SB is ingested in 
capsules compared to SB ingested in solution (19), meaning any conclusions in this paper are 
restricted to supplementation in gelatine capsules. 
Another important difference between studies is the provision of a meal before SB 

























Gough, et al. (8) requested their participants to refrain from food 4 hours before SB ingestion. It 
is possible that the time at which an individual consumes their pre-competition or training meal 
influences the subsequent response to SB ingestion. Although unexplored, the influence of meal 
ingestion on the pharmacokinetic responses to SB is of great practical implication. In our study, 
we opted to provide a standardised breakfast to better simulate a practical training or 
competition situation, assuming that athletes typically train or compete in a well-fed post-
prandial state. It must be noted, however, that although our pre-ingestion meal strategy 
represents the responses to SB ingestion under a general post-prandial state, we did not explore 
the impact of meal composition on these responses, which remain a largely overlooked topic of 
investigation. Another interesting point is that our ∆Cmax values (~+10 mmol∙L-1) were 
considerably higher than the +7 mmol∙L-1 shown by Gough, et al. (8) when supplemented with 
the same 0.3 g∙kg-1BM dose of SB. We speculate that this too could be explained, at least in 
part, by the timing of food intake prior to supplementation. Since our volunteers had eaten only 
one hour before supplementation, they could have been presenting a slight metabolic alkalosis 
due to the “alkaline tide” effect that accompanies food ingestion (20). Alternatively, the 
presence of food in their stomach could have resulted in higher luminal pH (21), which could 
result in less bicarbonate reacting with stomach acids, allowing more bicarbonate to enter the 
intestine to be absorbed. Differences in blood gas analysers and in blood collection methods 
(e.g., vein vs. capillary blood taken with or without arterialisation) may have also played some 
role in the different results between studies; however, it is important to note that different 
methods may yield different absolute values but they unlikely will result in an entirely different 
pharmacokinetic curve.  
Analysis of classical timings of bicarbonate supplementation (60, 90 and 120 min post 
ingestion) identified a progressive step pattern with significant increases over each 30 min 

























obtained 120 minutes post ingestion. However, given typical error at baseline was estimated as 
1.8 mmol∙L-1, differences can be explained by random errors, especially given the large number 
of data points measured and the probable extended plateau period. Nevertheless, mean values 
were very near or above the purported ergogenic thresholds in all time points. Importantly, there 
is currently no evidence for a linear association between the magnitude of the blood bicarbonate 
increase with the magnitude of the ergogenic effect of SB. Thus, one cannot assume that the 
higher the blood bicarbonate value, the greater the effects on performance. In fact, evidence so 
far points towards a minimum increase in blood bicarbonate necessary for SB to exert its 
ergogenic effects (4, 11, 12). In that sense, the Bayesian modelling presents a significant 
advance in data interpretation, as it allows for direct probabilistic questions to be addressed. For 
example, models can be used to estimate the probability that an individual from the population 
will experience an increase of at least +5 mmol·L-1 (or any other value) over a specified time 
interval. The Bayesian modelling clearly indicated a high probability for ergogenic effects 
(assuming the validity of the +5 and +6 mmol·L-1 thresholds) over a prolonged period of time 
although there was large inter-individual variability (Figure 2). Future research should 
corroborate the use of these ergogenic thresholds for exercise performance.  
Another aim of our study was to confirm whether blood bicarbonate responses and, 
more importantly, the time to peak in blood bicarbonate, are consistent across 3 identical trials 
conducted on different days. Although Cmax and ∆Cmax were similar between trials, we 
showed a significant difference in Tmax between trials, indicating poor repeatability of this 
measure. ICC and CV also showed moderate-to-poor reliability for these variables, especially 
∆Cmax and Tmax. In support of this, individual analysis also showed a considerable intra-
individual variability in blood bicarbonate responses to acute SB ingestion (Figure 2). Thus, we 
suggest that determination of Tmax for subsequent implementation prior to exercise may not be 
the most suitable method when ingesting SB in gelatine capsules. This moderate-to-poor 346 
reliability for blood bicarbonate measures shown in our study is somewhat in contrast with 347 
recent studies that showed consistent blood bicarbonate responses between trials (8, 14), but in 348 
agreement with a study that showed larger intra-individual variation in blood responses to SB 349 
ingestion (22). The large variation shown here may be a reflection of the long plateau-shaped 350 
curve we showed for blood bicarbonate, where values fluctuate around Cmax for a prolonged 351 
period, allowing the peak value to occur anytime within this period of time. This reinforces the 352 
notion that the peak value is, in our case, only slightly different than the other similarly elevated 353 
values, and that identification of a solitary peak value might represent random variation rather 354 
than a true peak value which would coincide with the best opportunity for SB to be ergogenic. 355 
Therefore, it appears likely that there is a broad window of opportunity, and not a single time 356 
point, where SB supplementation is more likely to be effective. This is supported by the 357 
Bayesian modelling used in the current study, and by previous studies showing no differences 358 
in the performance effects of SB between different time points following ingestion (23). Again, 359 
the differences between our results and those by Gough, et al. (8) might be due to different 360 
experimental settings (including pre-ingestion meal and SB being taken in capsules vs. 361 
dissolved in water), which might have resulted in different types of blood bicarbonate curve 362 
(i.e., long-plateau vs. sharp increase followed by sharp decrease). Nonetheless, further work 363 
should confirm our assertions by investigating the effect of SB supplementation on exercise 364 
performance performed at various time points following supplementation.  365 
Importantly, SB ingestion resulted in significant and frequent side-effects in all 366 
sessions, with no differences being shown between sessions. The consistent and widespread 367 
occurrence of important side-effects remains a major obstacle for SB use in practical settings, 368 
and this is yet to be solved. Future studies should look for ways to promote the ergogenic effects 369 
























 This study has some limitations. First, although we designed the experiment to have 
the highest possible external validity, we acknowledge that the participants remained rested for 
the entire experimental protocol. This means that the commencement of exercise, either a 
warm-up or a competition, could alter the time-responses shown herein. The exact window of 
ergogenic potential shown here can only be assumed to be valid if the athlete remains rested 
between SB ingestion and the beginning of the exercise. Future studies should examine how 
exercise of different intensities affect the pharmacokinetics and the time course of ergogenic 
properties of SB. Another limitation is the use of a single 0.3 g·kg-1 SB dose, which does not 
allow any extrapolation of the current findings to smaller doses (e.g., 0.2 g·kg-1) or other 
supplementation strategies (e.g., split-dose strategy). In fact, because previous studies showed 
a shorter period of blood bicarbonate elevations (above the purported ergogenic thresholds) 
with smaller doses (4), it is possible that time to peak remains as a relevant strategy when 
smaller doses are used, although this is yet to be confirmed. Indeed, the study by Gough, et al. 
(13) showed that individualised strategies based on time-to-peak may allow for the use of 
smaller doses without any measurable loss in SB ergogenicity. However, this study did not 
directly compare the effect of SB at time to peak with standard time points that are typically 
used in SB literature (e.g. 60-, 90- or 120-min following SB ingestion). Thirdly, we were unable 
to perform PO2 analysis in our samples, meaning we could not ensure venous blood 
arterialisation, despite the use of a thermal blanket specifically designed for the arterialisation 
of venous blood in the forearm. Lastly, the interpretation of our data is based on the current 
assumption that increases in +5 and +6 mmol‧ L-1 in blood bicarbonate are true thresholds for 
SB to be ergogenic. Since we were unable to associate the pharmacokinetic data with true 
performance effects in our participants, some caution should be exercised when extrapolating 
























To conclude, supplementation with SB in gelatine capsules following a standardized 
breakfast across three sessions showed only moderate reliability at the group level, but at the 
individual level, reliability appears to be poor. In particular, Tmax was not reproducible across 
the three sessions, suggesting it may not the most effective way by which to optimise SB 
supplementation. This is probably related to the long, sustained increases in blood bicarbonate 
following SB ingestion, so that solitary peak values are more a reflection of random error rather 
than true maximal increases in blood bicarbonate. Nonetheless, our data show that a 0.3 g·kg-1 
BM dose results in a long-lasting (~3 hours, staring from ~60 min after SB ingestion) window 
of ergogenic potential considering an ergogenic threshold of +5-6 mmol·L-1 in blood 
bicarbonate from baseline. This challenges the notion that SB ingestion individualised to time to 
peak is a necessary strategy, at least when a dose of 0.3 g·kg-1 is taken in gelatine capsules.  
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Figure 1. Panel A: Time course of mean blood bicarbonate (HCO3
-) responses following 
supplementation, determined during each of the 3 sodium bicarbonate (SB1 black circle; SB2 
dark grey square; SB3 light grey triangle) and placebo (PL; stars) trials, * different from PL; 
Panel B: Area under the curve (AUC) for blood bicarbonate in the 3 SB sessions; Panel C: 
Peak blood bicarbonate concentration (Cmax) in the 3 SB sessions; Panel D: maximum 
increase in blood bicarbonate from baseline (∆Cmax) in the 3 SB sessions; Panel E: Time to 
peak (Tmax), determined in the 3 SB sessions. Individual data are presented in circles; bars 
and error bars represent group mean and standard deviation, p-values represent adjusted 
within-subject effects. 
Figure 2. Individual data for blood bicarbonate increases after sodium bicarbonate 
supplementation (SB), on the three visits. Black bricks = peak bicarbonate concentration 
(Tmax); bricks filled with diagonal lines = +6 mmol∙L-1 or above; grey bricks = +5 - +5.9 
mmol∙L-1.  
Figure 3. Maximum increase in blood bicarbonate (HCO3
-) from baseline at classical timing 
points following sodium bicarbonate supplementation (60, 90 and 120 minutes following 
ingestion) and at time-to-peak (Tmax; 152 ± 47 minutes) determined from the 3 SB sessions. 
Dotted line at 5 and 6 mmol∙L-1 represents the theoretical thresholds of potential and almost 
certain ergogenic effects. Bars and error bars represent means and standard deviation across 
the three SB sessions. p-values represent adjusted within-subject effects.  
Figure 4. Density plot of simulated (n = 1 million) cubic time-course of blood bicarbonate 
across a 4-h period following the acute ingestion of 0.3 mg·kg-1 body mass of sodium 513 
bicarbonate. White triangles represent mean values from the data, and darker areas represent 514 











Supplemental figure 1: Panel A: Time course of mean pH responses following 
supplementation, determined during each of the 3 sodium bicarbonate (SB1 black circle; SB2 
dark grey square; SB3 light grey triangle) and placebo (PL; stars) trials, * different from PL; 
Panel B: Area under the curve (AUC) for pH in the 3 SB sessions; Panel C: pH peak (Cmax) 
in the 3 SB sessions; Panel D: maximum increase in pH from baseline (∆Cmax) in the 3 SB 
sessions; Panel E: Time to peak (Tmax) for pH, determined in the 3 SB sessions. Individual 
data are presented in circles; bars and error bars represent group mean and standard deviation. 
Supplemental figure 2: Side-effects. Size of circle refers the maximal side-effects intensity 




Intraclass correlation Typical error 
(mmol·L-1) 
Coefficient of Variation 
(%) 






SB3 2.5 97.5 2.5 97.5 
Baseline 0.389 0.208 0.665 1.77 1.64 1.94 5.88 6.97 7.65 
10 0.330 0.080 0.681 1.44 1.10 1.96 3.31 5.72 6.38 
20 0.268 0.002 0.664 1.92 1.44 2.62 9.40 8.25 8.63 
30 0.218 0.002 0.611 2.09 1.60 2.79 7.63 6.16 8.66 
40 0.453 0.037 0.764 1.93 1.47 2.71 6.20 4.92 8.87 
50 0.335 0.010 0.698 2.11 1.63 2.85 6.28 5.40 8.75 
60 0.318 0.007 0.709 2.16 1.66 2.92 7.34 6.03 6.24 
70 0.367 0.016 0.726 1.70 1.29 2.33 4.90 4.76 6.38 
80 0.361 0.013 0.717 1.80 1.37 2.50 4.03 6.86 5.04 
90 0.388 0.042 0.740 2.26 1.73 3.10 5.91 5.05 8.55 
100 0.338 0.007 0.686 2.43 1.88 3.33 6.64 7.10 7.94 
110 0.263 0.003 0.645 2.81 2.16 3.79 7.46 6.76 10.24 
120 0.305 0.008 0.679 2.49 1.92 3.35 7.24 4.19 8.65 
130 0.266 0.003 0.645 2.68 2.08 3.62 8.23 5.89 8.65 
140 0.083 <0.001 0.451 2.92 2.31 3.78 8.67 9.76 8.76 
150 0.108 <0.001 0.511 2.13 1.69 2.79 6.68 6.49 5.68 
160 0.123 <0.001 0.523 2.65 2.07 3.44 10.48 6.30 6.37 
170 0.036 <0.001 0.307 2.40 1.91 3.14 9.67 6.99 6.26 
180 0.049 <0.001 0.363 2.58 2.07 3.45 9.87 5.43 8.72 
200 0.214 0.002 0.606 2.37 1.84 3.11 8.13 5.87 6.14 
220 0.199 0.002 0.577 1.88 1.44 2.49 5.25 4.67 6.43 
240 0.218 0.002 0.633 2.10 1.63 2.76 7.59 3.77 7.40 
Cmax 0.459 0.100 0.790 1.580 1.040 2.078 5.41 4.31 6.16 
∆Cmax 0.294 0.002 0.694 2.104 1.429 2.633 19.55 24.41 29.98 
Tmax 0.568 0.263 0.823 31.01 20.95 41.07 32.58 20.72 21.85 
AUC 0.293 0.001 0.636 347.7 244.7 423.9 26.66 25.92 33.84 
1 Reliability analyses. Intraclass coefficient correlations (ranges from 0 to 1), typical error and 
coefficient of variation calculated for each time point across the three sodium bicarbonate 
supplementation sessions and for the time-to-peak blood bicarbonate (Tmax), peak blood bicarbonate 











0 0% 0% 
15 0% 0% 
30 0% 0% 
45 8.6% 0% 
60 69% 14% 
75 93% 60% 
90 97% 86% 
105 99% 93% 
120 99% 95% 
135 99% 96% 
150 99% 96% 
165 99% 95% 
180 98% 94% 
195 97% 92% 
210 95% 88% 
225 91% 80% 
240 85% 70% 
1 Probability estimates (%) of elevating blood bicarbonate above 5 mmol∙L-1 and 6 mmol∙L-1 (from baseline) at different time 
points following sodium bicarbonate ingestion. Probability values were estimated using Bayesian simulation (n = 1 million). 
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